Funding Opportunities

Open Date (Earliest Submission Date): February 13, 2025

Expiration Date: March 14, 2025

Funds Available and Anticipated Number of Awards
NIAID intends to commit an estimated total of $4,000,000 in FY 2026 to fund 3-5 awards.

Award Budget
Application budgets are not expected to exceed $700,000 in direct costs less consortium indirect (F&A) per year during the R61 Phase and $1,000,000 in direct costs less consortium indirect (F&A) per year during the R33 Phase. Requested budgets should reflect the actual needs of the proposed project.

Award Project Period
Applicants may request up to two years of support for the R61 phase, and up to three years of support for the R33 phase. The maximum project period for an application submitted in response to this NOFO cannot exceed five years total.

Find additional information here

Open Date (Earliest Submission Date): November 04, 2024

Expiration Date: December 05, 2024

Funds Available and Anticipated Number of Awards
NIAID intends to commit $6,000,000 in FY 2025 to fund 4-5 awards.

Award Budget
Application budgets are not expected to exceed $750,000 in direct costs per year, and should reflect the actual needs of the project. 

Award Project Period
The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Find additional information here
 

The RePORT International Coordinating Center (RICC) invites researchers to submit full proposals for the Cross Consortium Funding for the RePORT International Consortium. This initiative will provide a maximum of two (2) years of funding to support two (2) to three (3) projects to support the development of collaborations across the RePORT consortium. This competition is organized by the RICC and administered by CRDF Global on behalf of the National Institute of Allergies and Infectious Diseases (NIAID).   

Full proposals must be submitted to CRDF Global’s Cross Consortium intake inbox Cross-Consortium@crdfglobal.org no later than Friday, June 21, 2024 (23:59) U.S. Eastern Standard Time (EST). Proposals will undergo a round of peer evaluation. 

Please visit CRDF Global’s website to view the request for proposals for more information by following this link: https://www.crdfglobal.org/rfp/cross-consortium-funding-for-the-report-international-consortium/

The Tuberculosis Elimination Alliance (TEA), led by the Association of Asian Pacific Community Health Organizations (AAPCHO), Asian & Pacific Islander American Health Forum (APIAHF), Hepatitis B Foundation (HBF), and Stop TB USA, with the support of the Centers for Disease Control and Prevention’s (CDC) Division of TB Elimination, announced that it awarded a total of $250,000 to 12 community health organizations serving Asian, Asian American (A/AA), Native Hawaiian, and Pacific Islander (NH/PI), Hispanic/Latino and African American communities that are disproportionately impacted by tuberculosis (TB).

TEA offered a third cycle of 12 mini-grant awards totaling $250,000 to community providers that increase awareness and build capacity on TB testing and treatment. The newly awarded mini-grant recipients in this cycle are as follows:

• Arkansas Coalition of Marshallese (Springdale, AR)
• Asian Pacific Health Foundation (San Diego, CA)
• EthnoMed (Seattle, WA)
• Jericho Road Community Health Center (Buffalo, NY)
• Midwest Asian Health Association (Chicago, IL)
• Mission Neighborhood Health Center (San Francisco, CA)
• Regional Pacific Islander Taskforce (San Francisco, CA)
• Revive Community Health (Tempe, AZ)
• Rural Women's Health Project (Gainesville, FL)
• San Diego County Medical Society Foundation, dba Champions for Health (San Diego, CA)
• Todu Guam Foundation, Ltd. (Tamuning, Guam)
• We Are TB / Somos TB (National)

Since its inception in 2019, TEA has distributed over $800,000 in mini-grant funding to 36 organizations. TEA, our members, partners, and mini-grantees look forward to building on the progress that we have made so far towards TB elimination. 

For more information on TEA, please visit www.tbeliminationalliance.org.

Open Date (Earliest Submission Date): October 05, 2023

Expiration Date: July 17, 2026

This Notice of Special Interest (NOSI) encourages applications that seek to better understand Pulmonary Non-Tuberculous Mycobacteria (NTM) Infections and inform development of medical countermeasures. This NOSI aims to stimulate advances in diagnosis and treatment of NTM infections that cause or exacerbate pulmonary disease such as Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii.

For more information, click here

Due Dates: October 11, 2023

Open Date: Earliest Submission Date: September 11, 2023

The purpose of this Notice of Funding Opportunity (NOFO) is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies. This Notice of Funding Opportunity (NOFO) will support mechanistic studies of early Mtb infection (defined as the time between Mtb exposure and early-stage granuloma formation) in the airway and lung with the ultimate goal of understanding these events in the setting of HIV co-infection.   

More information here

The Peer Reviewed Medical Research Program (PRMRP), established in fiscal year 1999 (FY99), has supported research across the full range of science and medicine, with an underlying goal of enhancing the health, care, and well-being of military Service Members, Veterans, retirees, and their family members.

FY2023 Funding Mechanisms have been announced! The Congressionally Directed Topic Areas include:

• Clinical Trial Award (CTA)
• Discovery Award (DA)
• Focused Program Award (FPA)
• Investigator-Initiated Research Award (IIRA)
• Lifestyle and Behavioral Health Interventions Research Award (LBIRA)
• Technology/Therapeutic Development Award (TTDA)

Letter of Intent is Due: April 19th, 2023

Full Applications are Due: May 31st, 2023

Learn more about this opportunity at https://cdmrp.health.mil/funding/prmrp

Open Date (Earliest Submission Date): February 05, 2023

Expiration Date: January 08, 2026

The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission.

For more information click here

The purpose of the proposed contract will be to provide a Mycobacterium tuberculosis (MTB) Quality Assessment Program (TBQA), a resource to: (1) support the ability of laboratories (Labs) to reliably perform study-specified MTB tests; (2) evaluate MTB technologies and specimen processes for use in clinical investigations; and (3) disseminate technical and scientific data.

Notice ID: 75N93022R00015

• Original Published Date: Aug 31, 2022 08:19 am EDT
• Original Date Offers Due: Nov 30, 2022 03:00 pm EST

For more info, click here